Altus Pharmaceuticals News

It's been hard to lose during the spectacular stock market boom of 2009. Hard, but not impossible.

Beleaguered drug maker Altus Pharmaceuticals Inc. of Waltham filed Wednesday for Chapter 7 bankruptcy - a step that usually results in liquidation of a company's assets.

Altus Pharmaceuticals Inc. said in a regulatory filing that it is "determined to commence a process to wind down the business" of the Waltham company.

Altus Pharmaceuticals Inc. today announced that on September 15, 2009, the Company received a letter from the Nasdaq Listing Qualifications Department notifying the Company that, for the last 30 consecutive business days, the bid price of the Companya s common stock has closed below the minimum $1.00 per share required for continued listing on the ...

Waltham, MA-based Altus Pharmaceuticals, a developer of protein-based drugs, revealed in an SEC filing yesterday that it decided last week a oewind downa the companya s operations.

Drug developer Altus Pharmaceuticals Inc. is winding down its business and has engaged creditors and vendors to "maximize the value of its assets," the company said in a regulatory filing late Monday.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Altus Pharmaceuticals Inc. has announced that the Nasdaq Stock Market told the company it has until Aug.

Altus Pharmaceuticals Inc. said the Nasdaq Stock Market has set an Aug. 24 deadline for the company to establish a plan to regain compliance with the exchange, or risk being delisted.

Altus Pharmaceuticals Inc. could run out of cash at the end of next month if the drug developer is unable to sign a partnership or other financial deal to remain as a going concern, according to a regulatory filing.

Xcellerex Inc., a privately held provider of manufacturing systems for biotherapeutics and vaccines, has named Jonathan Lieber as its chief financial officer.

Jul 9, 2009 - Xcellerex, Inc. announced today the appointment of Jonathan Lieber as Chief Financial Officer.

Disease foundations that are taking an increasing role in capital formation for local biotechs are nervously watching as the stock market and private capital markets wreak havoc with the companies that may hold the key to their future cures.

Drug developer Altus Pharmaceuticals Inc. has terminated its supply agreement with Lonza Ltd.

Pharmaceutical companies that were among the first to flee Cambridge for cheaper offices in the suburbs are now shedding space as revenue and head counts continue to shrink.

Main Category: Pediatrics / Children's Health Also Included In: Clinical Trials / Drug Trials Article Date: 12 Jun 2009 Altus Pharmaceuticals Inc.

Three years after Altus Pharmaceuticals Inc. went public and raised $105 million in a single day, the Cambridge biotechnology company is running out of money, and its stock, which once traded for more than $25 a share, closed at 40 cents yesterday.

On Monday, May 11, 2009 before the market opens, Altus Pharmaceuticals Inc. expects to report its results for the quarter ended March 31, 2009.

Just weeks after presiding over a 107-employee layoff and a senior-management reshuffling, drug maker Altus Pharmaceuticals Inc.

April 17, 2009 StandoutStocks.com "Stocks that Standout" picks for today are: Alnara Pharmaceuticals, Inc.